Drugs / Recifercept
Recifercept
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05061277 | Oct → Dec 2023 | — | Pfizer | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04543344 | Sep 2020 → Aug 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04410809 | Jan 2018 → Nov 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05116046 | Dec 2021 → Dec 2022 | achondroplasia | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT04638153 | Dec 2020 → Jan 2023 | achondroplasia | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recifercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04638153 ↗ |
| Known as | PF-07256472 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650420 ↗ |
| Known as | TA-46 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04410809 ↗ |
| Modality | Protein / enzyme biologic | “Decoy protein of the fibroblast growth factor receptor 3” NCT04410809 ↗ |
| Route | Subcutaneous | “sc solution for injection/infusion” NCT04410809 ↗ |